Latest News

Murali Janakiram, MD, MS
Immune Effector Cell Therapy Associated With Longer PFS After Ide-Cel Relapse in R/R MM

February 22nd 2024

Differences between IEC and non-IEC post-relapse outcomes showed some significance in PFS but not in ORR.

Aimee C. Talleur, MD, a physician at St. Jude Children’s Research Hospital
Aimee C. Talleur, MD, on the Challenge of Evaluating Late Effects from CAR-T in Pediatric Patients

February 22nd 2024

Wen Luo, PhD
IL1RAP, CAR, TGFβi, CXCR2 Modified NK Cells Enhances In Vitro Efficacy in Ewing Sarcoma

February 22nd 2024

Zachary Crees, MD, on the Potential of Cell Therapy to Treat or Prevent Viral Infections After HSCT
Zachary Crees, MD, on the Potential of Cell Therapy to Treat or Prevent Viral Infections After HSCT

February 22nd 2024

Susan Rheingold, MD
Analysis Informs Need for New Staging, Therapeutic Evaluations for EMD in B-ALL Prior to CAR T-Cell Therapy

February 21st 2024

Video Interviews

Conference Coverage

View All
Murali Janakiram, MD, MS
Immune Effector Cell Therapy Associated With Longer PFS After Ide-Cel Relapse in R/R MM

February 22nd 2024

Wen Luo, PhD
IL1RAP, CAR, TGFβi, CXCR2 Modified NK Cells Enhances In Vitro Efficacy in Ewing Sarcoma

February 22nd 2024

Susan Rheingold, MD
Analysis Informs Need for New Staging, Therapeutic Evaluations for EMD in B-ALL Prior to CAR T-Cell Therapy

February 21st 2024

E. Antonio Chiocca, MD, PhD
ACGT Awards Research Grant to Develop Oncolytic Virus for Glioblastoma

February 20th 2024

All News

© 2024 MJH Life Sciences

All rights reserved.